# Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

> **NCT06016387** · PHASE2 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 30 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- LMD

## Interventions

- **DRUG:** Tucatinib 150 MG
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **RADIATION:** Brain & Spinal Radiation

## Key facts

- **NCT ID:** NCT06016387
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-10-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016387, "Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06016387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*